ReviewInternational journal of molecular sciences2021
Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Towards the standardization of human platelet lysate production and its comparison to fetal bovine serum for human hematopoietic cell culture: a scoping review.Frontiers in toxicology · 2025Pooled it
- Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.International journal of molecular sciences · 2022Pooled it
- From Donation to Innovation: New Blood-Derived Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Platelet Lysate-Enriched Human Induced Pluripotent Stem Cell-Derived Chondrocyte Sheets for Bone Defect Repair via Endochondral Ossification.Advanced healthcare materials · 2026Article
- Transforming PRP into a shelf-stable therapy: Lyophilization preserves angiogenic and regenerative properties.Iranian journal of basic medical sciences · 2026Article
- Plasma-Depleted Lyophilized Porcine Platelet Lysate as an Alternative to Fetal Bovine Serum in Cell Culture.Life (Basel, Switzerland) · 2025Article
- Blood derivatives as monotherapy and combination therapy: A promising strategy for wound healing.Regenerative therapy · 2025Review
- Advances in Innovative Surgical Implant Manufacturing for Hernia Repair and Soft Tissue Reconstruction.Bioengineering (Basel, Switzerland) · 2025Review
- Human platelet lysate standardization across three independent European blood establishments.Stem cell research & therapy · 2025Article
- Human Platelet Lysate Treatment for Exposure Keratopathy: An In Vivo Confocal Microscopy and Anterior Segment OCT Study.Investigative ophthalmology & visual science · 2025Article
- Animal origins free products in cell culture media: a new frontier.Cytotechnology · 2025Review
- Mesangiogenic progenitor cells: a mesengenic and vasculogenic branch of hemopoiesis? A story of neglected plasticity.Frontiers in cell and developmental biology · 2025Article
- Central memory-enriched Vγ9Vδ2 γδ T cells via TGF-β expansion demonstrate enhancedFrontiers in immunology · 2025Article
- Lyophilized human platelet lysate: manufacturing, quality control, and application.Frontiers in cell and developmental biology · 2025Article
- Impact of increasingly complex cell culture conditions on the proteome of human periodontal ligament stem cells.Regenerative medicine · 2025Article
- Fetal bovine serum: how to leave it behind in the pursuit of more reliable science.Frontiers in toxicology · 2025Review
- Calcium Chloride vs. Mechanical Preparation of Fibrinogen-Depleted Human Platelet Lysate: Implications for Umbilical Cord Mesenchymal Stem Cell Culture.Life (Basel, Switzerland) · 2024Article
- Bioprocessing of human platelet concentrates to generate lysates and extracellular vesicles for therapeutic applications.MethodsX · 2024Article
- Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells.International journal of molecular sciences · 2024Article
- The Biological Effect of Enriching the Plasma Content in Platelet-Rich Plasma: An In Vitro Study.Biomolecules · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.